The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors
E. Puca, P. Probst, M. Stringhini, P. Murer, G. Pellegrini, S. Cazzamalli, C. Hutmacher, B. Gouyou, S. Wulhfard, M. Matasci, A. Villa, D. Neri
This paper describes a fusion protein that delivers interleukin-12 to tumors, enhancing NK and CD8+ T cell activity and synergizing with checkpoint inhibitors.
bioRxiv · Jul 3, 2019Cancer Biology